UCB0942

DRUG3 trials

Sponsors

UCB Biopharma S.P.R.L., UCB Biopharma SRL

Conditions

Healthy Japanese and Caucasian SubjectsHighly Drug-resistant Focal Epilepsy

Phase 1

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UCB0942 in Healthy Japanese and Caucasian Subjects

CompletedNCT03168984

UCB Biopharma S.P.R.L.Healthy Japanese and Caucasian Subjects

Start: 2017-05-05End: 2017-08-14Updated: 2017-08-22

Phase 2

A Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy

CompletedNCT02495844

UCB Biopharma S.P.R.L.Highly Drug-resistant Focal Epilepsy

Start: 2015-07-31End: 2017-07-31Updated: 2019-02-05

An Open-label Extension Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy

TerminatedNCT02625090

UCB Biopharma SRLHighly Drug-resistant Focal Epilepsy

Start: 2015-12-03End: 2020-11-24Updated: 2022-03-09

Related Papers

Efficacy and safety of adjunctive padsevonil in adults with drug‐resistant focal epilepsy: Results from two double‐blind, randomized, placebo‐controlled trials

Epilepsia Open2022-09-3023 citations

Padsevonil randomized Phase IIa trial in treatment-resistant focal epilepsy: a translational approach

Brain Communications2020-01-0124 citations